Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors

Vaccine. 2009 Oct 19;27(44):6148-53. doi: 10.1016/j.vaccine.2009.08.022. Epub 2009 Aug 25.

Abstract

We evaluated individual and bivalent replicon vaccines against Clostridiumbotulinum neurotoxin serotypes A (BoNT/A) or B (BoNT/B). The DNA replicon vaccine (pSCARSBHc) encoding the Hc domain of BoNT/B (BHc) induced better responses and protection against BoNT/B mouse challenge than conventional DNA vaccine. The dual-expressing DNA vaccine (pSCARSA/BHc) protected similarly to a DNA replicon vaccine mixture (pSCARSAHc+pSCARSBHc). Additionally, recombinant SFV particles, VRP-AHc or VRP-BHc, protected mice from high-dose BoNT/A or BoNT/B challenge, respectively. Mice given either dual-expressing VRP-A/BHc or mixture of VRP-AHc and VRP-BHc were protected from challenge with serotype A/B mixtures. These data justify further testing in other animals or humans.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antibodies, Bacterial / blood
  • Bacterial Vaccines / genetics
  • Bacterial Vaccines / immunology*
  • Botulinum Toxins / genetics
  • Botulinum Toxins / immunology*
  • Botulinum Toxins, Type A / genetics
  • Botulinum Toxins, Type A / immunology*
  • Botulism / immunology
  • Botulism / prevention & control*
  • Clostridium botulinum / immunology
  • Female
  • Mice
  • Mice, Inbred BALB C
  • Replicon
  • Semliki forest virus / immunology
  • Vaccines, DNA / genetics
  • Vaccines, DNA / immunology

Substances

  • Antibodies, Bacterial
  • Bacterial Vaccines
  • Vaccines, DNA
  • rimabotulinumtoxinB
  • Botulinum Toxins
  • Botulinum Toxins, Type A